Rituximab: A review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large b-cell lymphoma

Drugs

Volumn 70, Issue 11, 2010, Pages 1445-1476

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Chronic lymphocytic leukaemia; Non Hodgkins lymphoma; Rituximab, general

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; METHYLPREDNISOLONE; MITOXANTRONE; PENTOSTATIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; ARTHRALGIA; ASTHENIA; BACKACHE; CANCER RELAPSE; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HUMAN; HYPOTENSION; INFECTION; INJECTION SITE REACTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NIGHT SWEAT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHARMACODYNAMICS; PRURITUS; RASH; REMISSION; REVIEW; RHINITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; AGED; COST BENEFIT ANALYSIS; FEMALE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED;

EID: 77954557374     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11201110-000000000-00000     Document Type: Review

References (119)

1. Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009 Mar; 8 (2): 223-235
2. Foster T, Miller JD, Boye ME, et al. Economic burden of follicular non-Hodgkin's lymphoma. Pharmacoeconom-ics 2009; 27 (8): 657-679
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology™: non-Hodgkin's lymphoma (v.1. 2010) [online]. Available from URL: http://www.nccn.org/professionals/physician-gls/PDF/nhl.pdf [Accessed 2010 Mar 22]
4. Robak T, Dmoszynska A, Solal-Celigny P. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010 Apr 1; 28 (10): 1756-1765
5. Hagemeister F. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2010; 70 (3): 261-272
6. Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program 2007: 233-242
7. Sonet A, Bosly A. Rituximab and chemotherapy in diffuse large B-cell lymphoma. Expert Rev Anticancer Ther 2009 Jun; 9 (6): 719-726
8. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005 Mar 24; 24 (13): 2121-2143
9. Genentech, Inc. Rituxan (rituximab) injection for intravenous use: US prescribing information [online]. Available from URL: http://www.gene.com/gene/ products/information/pdf/rituxan-prescribing.pdf [Accessed 2010 Mar 22]
10. European Medicines Agency. MabThera (rituximab) 100mg (10mg/mL) concentrate for solution for infusion: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/ Mabthera/emea-combined-h165en.pdf [Accessed 2010 Mar 22]
11. Vega MI, Huerta-Yepez S, Martinez-Paniagua M, et al. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res 2009 Nov 1; 15 (21): 6582-6594
12. Vega MI, Huerta-Yepez S, Jazirehi AR, et al. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 2005 Dec 8; 24(55): 8114-8127
13. Foon KA, Hallek MJ. Changing paradigms in the treat-ment of chronic lymphocytic leukemia. Leukemia 2010 Mar; 24 (3): 500-511
14. Selenko N, Majdic O, Draxler S, et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001 Oct; 15 (10): 1619-1626
15. Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007 Apr; 62 (1): 43-52
16. Tran L, Huitema ADR, Aarden L, et al. Phamacokinetics of rituximab and the development of antibodies against rituximab in patients with a B-cell CD20+ malignancy [abstract no. 0975]. 14th Congress of the European He-matology Association; 2009 Jun 4-7; Berlin
17. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Asso-ciation of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998 Sep; 9 (9): 995-1001
18. Blasco H, Chatelut E, Benz de Bretagne I, et al. Pharm-acokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. Fundam Clin Pharmacol 2009 Oct; 23 (5): 601-608
19. Rodriguez J, Gutierrez A. Pharmacokinetic properties of rituximab. Rev Recent Clin Trials 2008 Jan; 3 (1): 22-30
20. Li J, Levi M, Charoin J-E, et al. Rituximab exhibits a long half-life based on a population pharmacokinetic analysis in non-Hodgkin's lymphoma (NHL) patients [abstract no. 2371]. Blood 2007 Nov 16; 110 (11 Pt 1): 700
21. Scheidhauer K, Wolf I, Baumgartl H-J, et al. Biodistribu-tion and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2002 Oct; 29 (10): 1276-1282
22. Li J, Zhi J, Wenger MK, et al. Higher doses of rituximab may be required for patients with CLL as compared to NHL based on population pharmacokinetic (PK) modelling [abstract no. 1742]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
23. Yin A, Li J, Hurst D, et al. Population pharmacokinetics (PK) and association of PK and clinical outcomes of ri-tuximab in patients with non-Hodgkin's lymphoma [abstract no. 13108]. 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 4-8; Chicago (IL)
24. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994 Sep 1; 84 (5): 1361-1392 (Pubitemid 24273002)
25. Harris NL, Jaffe ES, Diebold J, et al. World Health Orga-nization classification of neoplastic diseases of the hema-topoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting: Airlie House, Virginia, November 1997. J Clin Oncol 1999 Dec; 17 (12): 3835-3849
26. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981 Jul 1; 48 (1): 198-206
27. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975 Aug; 46 (2): 219-234
28. Zinzani PL. Lymphoma: diagnosis, staging, natural his-tory, and treatment strategies. Semin Oncol 2005 Feb; 32 (1 Pt 2): 4-10
29. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996 Jun 15; 87 (12): 4990-4997
30. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 Jun 15; 111 (12): 5446-5456
31. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999 Apr; 17 (4): 1244-1253
32. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007 Feb 10; 25 (5): 579-586
33. Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group [abstract no. 535]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
34. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclo-phosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005 Jun 20; 23 (18): 4079-4088
35. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008 Aug 15; 112 (4): 975-980
36. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005 Jun 20; 23 (18): 4070-4078 (Pubitemid 46211312)
37. Lepretre S, Aurran T, Mahe B, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophos-phamide (C) and MabCampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group on CLL and WM (FCGCLL/MW) and the 'Groupe Ouest-Est d'Etudes Des Leucemies Aigues et Autres Maladies du Sang' (GOELAMS): CLL2007FMP (for fit medically patients) [abstract no. 538]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
38. Groupe Ouest Est d'Etude des Leucemies et Autres Mala-dies du Sang GOELAMS. Fludarabine, cyclophos-phamide, and rituximab or alemtuzumab in treating patients with B-cell chronic lymphocytic leukemia [Clin-icalTrials.gov identifier NCT00564512]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from: http://www.clinicaltrials.gov [Accessed 2010 Mar 25]
39. Del Poeta G, Del Principe MI, Maurillo L, et al. Oral flu-darabine plus rituximab result in high complete remission rate in B-cell chronic lymphocytic leukemia [abstract no. 0094]. Haematologica 2008 Jun 1; 93 Suppl. 1: 37
40. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG) [abstract no. 205]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
41. Hillmen P, Gribben JG, Follows GA, et al. An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL) [abstract no. 3428]. 51st Annual Meeting and Exposition of the American Society of Hematol-ogy; 2009 Dec 5-8; New Orleans (LA)
42. Kay NE, Geyer SM, Call TG, et al. Combination chemo-immunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007 Jan 15; 109 (2): 405-411
43. Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, flu-darabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009 Sep 20; 27 (27): 4578-4584
44. Faderl S, Wierda W, O'Brien S, et al. Fludarabine, cyclo-phosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 years. Leuk Res 2010 Mar; 34(3): 284-288
45. Frankfurt O, Hamilton E, Duffey S, et al. Alemtuzumab and rituximab combination therapy for patients with untreated CLL: a phase II trial [abstract no. 2098]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)
46. Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzu-mab and rituximab. Cancer 2008 Oct 15; 113 (8): 2110-2118
47. Parikh SA, Keating M, O'Brien S, et al. Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in high-risk chronic lymphocytic leukemia [abstract no. 208]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
48. Wierda WG, O'Brien S, Ferrajoli A, et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and ri-tuximab (CFAR), an active frontline regimen for high-risk patients with CLL [abstract no. 628]. Blood 2007 Nov 16; 110 (11 Pt 1): 194a
49. Castro JE, James DF, Sandoval-Sus JD, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009 Oct; 23 (10): 1779-1789
50. Eichhorst BF, Fischer K, Fink A-M, et al. Health related quality of life (HRQOL) in patients receiving chemo-immunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) or fludarabine and cyclo-phosphamide (FC) for first line therapy with advanced chronic lymphocytic leukemia (CLL) [abstract no. 3438]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
51. Fischer K, Stilgenbauer S, Schweighofer CD, et al. Ben-damustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL study group (GCLLSG) [abstract no. 330]. 50th Annual Meeting and Exposition of the American Society of He-matology; 2008 Dec 6-9; San Francisco (CA)
52. Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and ri-tuximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008 Jan 10; 26 (2): 196-203
53. Tsimberidou A-M, Wierda W, Plunkett W, et al. Ox-aliplatin, fludarabine, cytarabine, and rituximab combination therapy induces high response rates in agressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS) [abstract no. 3443]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
54. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006 Apr 1; 24 (10): 1575-1581
55. Lamanna N, Heaney ML, Brentjens RJ, et al. Pentostatin, cyclophosphamide, rituximab, and mitoxantrone: a new highly active regimen for patients with chronic lympho-cytic leukemia (CLL) previously treated with PCR or FCR [abstract no. 3115]. Blood 2007 Nov 16; 110 (11 Pt 1): 916
56. Faderl S, Ferrajoli A, Wierda W, et al. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukaemia recurrence. Cancer 2010 Mar 15; 116 (10): 2360-2365
57. Badoux XC, Keating M, O'Brien S, et al. Chemoimmuno-therapy with cyclophosphamide, fludarabine, alemtuzumab and rituximab (CFAR) is effective in relapsed patients with chronic lymphocytic leukemia (CLL) [abstract no. 3431]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
58. Bowen DA, Call TG, Jenkins GD, et al. Methylpredniso-lone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lym-phoma 2007 Dec; 48 (12): 2412-2417
59. Castro JE, Sandoval-Sus JD, Bole J, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008 Nov 1; 22 (11): 2048-2053
60. Dungarwalla M, Evans SO, Riley U, et al. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy [letter]. Haematologica1 2008 Mar; 93 (3): 475-476
61. Robak T, Aultman R, Oertel SHK, et al. Quality-adjusted survival (Q-TWiST) analysis of patients with relapsed or refractory chronic lymphocytic leukaemia treated with rituximab plus fludarabine and cyclophosphamide (R-FC) versus FC alone [abstract no. 1368]. 51st Annual Meeting and Exposition of the American Society of Hematology 2009 Dec 5-8; New Orleans (LA)
62. Feuring-Buske M, Kneba M, Unterhalt M, et al. IDEC-C2B8 (rituximab) anti-CD20 antibody treatment in re-lapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000 Sep; 79 (9): 493-500
63. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997 Sep 15; 90 (6): 2188-2195
64. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000 Sep; 18 (17): 3135-3143
65. Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999 Jun; 17 (6): 1851-1857
66. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended ri-tuximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodg-kin's lymphoma. Ann Oncol 1999; 10 (6): 655-661
67. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Ritux-imab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998 Aug; 16 (8): 2825-2833
68. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study. J Clin Oncol 2007 May 20; 25 (15): 1986-1992
69. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and predni-sone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005 Dec 1; 106 (12): 3725-3732
70. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008 Oct 1; 26 (28): 4579-4586
71. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008 Dec 15; 112 (13): 4824-4831
72. Rummel MJ, Niederle N, Maschmeyer G, et al. Benda-mustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract no. 405]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
73. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and pred-nisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009 Apr 1; 27 (10): 1607-1614
74. Marcus R, Aultman R, Jost F. A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodg-kin's lymphoma. Br J Cancer 2010 Jan 5; 102 (1): 19-22
75. van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006 Nov 15; 108 (10): 3295-3301
76. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment ofrelapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. Epub 2010 May 3
77. Foran JM, Gupta RK, Cunningham D, et al. A UK mul-ticentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lympho-ma, with PCR monitoring of molecular response. Br J Haematol 2000 Apr; 109 (1): 81-88
78. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 Jan 24; 346 (4): 235-242
79. Habermann TM, Weller EA, Morrison VA, et al. Ritux-imab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lym-phoma. J Clin Oncol 2006 Jul 1; 24 (19): 3121-3127
80. Pfreundschuh M, Trumper L, Osterborg A. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006 May; 7 (5): 379-391
81. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without ri-tuximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008 Feb; 9 (2): 105-116
82. Delarue R, Tilly H, Salles G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA study [abstract no. 406]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
83. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005 Jun 20; 23 (18): 4117-4126
84. Coiffier B, Gisselbrecht C, Bosly A, et al. 10 years follow-up of the GELA LNH98.5 study, first randomized study comparing R-CHOP to CHOP chemotherapy in patients with diffuse large B-cell lymphoma [abstract no. 3741]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
85. Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without ri-tuximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009 Apr 23; 113 (17): 3896-3902
86. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009 May 14; 113 (20): 4834-4840
87. Hornberger J, Reyes C, Lubeck D, et al. Economic eva-luation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma 2008 Feb; 49 (2): 227-236
88. Ray JA, Carr E, Lewis G, et al. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodg-kin's lymphoma in the UK. Value Health. Epub 2010 Jan 8
89. Deconinck E, Miadi-Fargier H, Le Pen C, et al. Cost ef-fectiveness of rituximab maintenance therapy in follicular maintenance therapy in follicular lymphoma: long-term economic evaluation. Pharmacoeconomics 2010; 28 (1): 35-46
90. Hayslip JW, Simpson KN. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission. Clin Lymphoma Myeloma 2008 Jun; 8 (3): 166-170
91. Kasteng F, Erlanson M, Hagberg H, et al. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol 2008; 47 (6): 1029-1036
92. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005 Apr 15; 103 (8): 1644-1651
93. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmu-notherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009 Feb 1; 27 (4): 498-503
94. Lamanna N, Jurcic JG, Noy A, et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009 Feb 1; 27 (4): 491-497
95. Ahmadi T, Schuster SJ. Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned? J Clin Oncol 2009 Feb 1; 27 (4): 479-480
96. National Cancer Institute. Adult non-Hodgkin's lymphoma treatment (PDQ®) health professional version [online]. Available from URL: http://www.cancer.gov/cancerinfo/pdq/treat ment/adult-non-hodgkins/ healthprofessional [Accessed 2010 Mar 22]
97. Horning SJ. Follicular lymphoma, survival, and rituximab: is it time to declare victory? J Clin Oncol 2008 Oct 1; 26 (28): 4537-4538
98. van Oers MHJ. Rituximab maintenance therapy: a step forward in follicular lymphoma. Haematologica 2007 Jun; 92 (6): 826-33 99.
99. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009 Feb 18; 101 (4): 248-255
100. Salles GA, Seymour JF, Feugier P, et al. Rituximab main-tenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to chemotherapy [abstract no. 8004]. 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 4-8; Chicago (IL)
101. Eastern Cooperative Oncology Group. Rituximab in treat-ing patients with low tumor burden indolent non-Hodgkin's lymphoma [ClinicalTrials.gov identifier NCT00075946]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Apr 19]
102. Ternant D, Henin E, Cartron G, et al. Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. Br J Clin Pharmacol 2009 Oct; 68 (4): 561-573
103. Sehn LH, Donaldson J, Filewich A, et al. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 2007 May 15; 109 (10): 4171-4173
104. National Cancer Institute. Chronic lymphocytic leukemia treatment (PDQ®) health professional version [online]. Available from URL: http://www.cancer.gov/cancertopics/pdq/treatment/CLL/healthprofessional/ allpages [Accessed 2010 Mar 22]
105. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lym-phoma international prognostic index. Blood 2004 Sep 1; 104 (5): 1258-1265
106. A predictive model for aggressive non-Hodgkin's lympho-ma: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993 Sep 30; 329 (14): 987-994
107. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard In-ternational Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010 May 10; 28 (14): 2373-2380
108. Czuczman MS, Grillo-Lopez AJ, Alkuzweny B, et al. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Leuk Lymphoma 2006 Sep; 47 (9): 1830-1840
109. Maeshima AM, Taniguchi H, Nomoto J, et al. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy. Cancer Sci 2009 Jan; 100 (1): 54-61
110. Winter JN, Li S, Aurora V, et al. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clin Cancer Res 2010 Apr 15; 16 (8): 2435-2442
111. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003 Nov 1; 21 (21): 3940-3947
112. Friedberg JW, Younes A, Fisher DC, et al. Durable re-sponses in patients treated with galiximab (anti-CD80) in combination with rituximab for relapsed or refractory follicular lymphoma: long-term follow-up of a phase II clinical trial [abstract no. 1004]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)
113. Blum KA, Baiocchi RA, Alinari L, et al. A phase II trial of induction plus maintenance rituximab and bortezomib in patients with relapsed/refractory mantle cell (MCL) and follicular (FL) non-Hodgkin's lymphoma [abstract no. 3053]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)
114. David KA, Smith MR, Lossos IS, et al. A phase II trial of combination bortezomib (Velcade®) and rituximab for untreated 'high tumor burden' indolent non-Hodgkin lymphoma [abstract no. 2004]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)
115. Pregno P, Chiappella A, Zinzani PL, et al. Activity and safety of bortezomib and rituximab in relapsed/refractory indolent non follicular and mantle-cell non Hodgkin lymphoma: a phase II multicenter study by Intergruppo Italiano Linfomi [abstract no. 0411]. 14th Congress of the European Hematology Association; 2009 Jun 4-7; Berlin
116. Fowler N, McLaughlin P, Hagemeister FB, et al. A biolo-gic combination of lenalidomide and rituximab for frontline therapy of indolent B-cell non-Hodgkin's lymphoma [abstract no. 1714]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
117. Dutia M, DeRoock I, Chee K, et al. R2: preliminary results of a phase II study of lenalidomide and rituximab in relapsed/refractory indolent non-Hodgkin's lymphoma (NHL) [abstract no. 1679]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
118. Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2 study of lumi-liximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010 Jan 21; 115 (3): 489-495
119. Ferrajoli A, Badoux XC, O'Brien S, et al. Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) [abstract no. 206]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)